Lv Min, Qiu Jian-Ge, Zhang Wen-Ji, Jiang Qi-Wei, Qin Wu-Ming, Yang Yang, Zheng Di-Wei, Chen Yao, Huang Jia-Rong, Wang Kun, Wei Meng-Ning, Cheng Ke-Jun, Shi Zhi
Institute of Materia Medica, Zhejiang Chinese Medical University Hangzhou, Zhejiang, China.
Department of Cell Biology & Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University Guangzhou, Guangdong, China.
Am J Transl Res. 2016 Jul 15;8(7):2969-80. eCollection 2016.
Overexpression of ABCB1 in cancer cells is one of the main reasons of cancer multidrug resistance (MDR). Wallichinine is a compound isolated from piper wallichii and works as an antagonist of platelet activiating factor receptor to inhibit the gathering of blood platelet. In this study, we investigate the effect of wallichinine on cancer MDR mediated by ABCB1 transporter. Wallichinine significantly potentiates the effects of two ABCB1 substrates vincristine and doxorubicin on inhibition of growth, arrest of cell cycle and induction of apoptosis in ABCB1 overexpressing cancer cells. Furthermore, wallichinine do not alter the sensitivity of non-ABCB1 substrate cisplatin. Mechanistically, wallichinine blocks the drug-efflux activity of ABCB1 to increase the intracellular accumulation of rhodamine 123 and doxorubicin and stimulates the ATPase of ABCB1 without alteration of the expression of ABCB1. The predicted binding mode shows the hydrophobic interactions of wallichinine within the large drug binding cavity of ABCB1. At all, our study of the interaction of wallichinine with ABCB1 presented herein provides valuable clues for the development of novel MDR reversal reagents from natural products.
ABCB1在癌细胞中的过表达是癌症多药耐药(MDR)的主要原因之一。瓦氏千里光宁是从石南叶胡椒中分离出的一种化合物,作为血小板活化因子受体的拮抗剂,可抑制血小板聚集。在本研究中,我们研究了瓦氏千里光宁对ABCB1转运蛋白介导的癌症多药耐药的影响。瓦氏千里光宁显著增强了两种ABCB1底物长春新碱和阿霉素对ABCB1过表达癌细胞生长抑制、细胞周期阻滞和凋亡诱导的作用。此外,瓦氏千里光宁不会改变非ABCB1底物顺铂的敏感性。从机制上讲,瓦氏千里光宁阻断ABCB1的药物外排活性,增加罗丹明123和阿霉素的细胞内积累,并刺激ABCB1的ATP酶,而不会改变ABCB1的表达。预测的结合模式显示了瓦氏千里光宁在ABCB1的大药物结合腔内的疏水相互作用。总之,我们在此对瓦氏千里光宁与ABCB1相互作用的研究为从天然产物开发新型多药耐药逆转剂提供了有价值的线索。